CALT News and Press, Calliditas Therapeutics AB From 07/15/22

The European Commission has approved Calliditas Therapeutics' ( NASDAQ: CALT ) Kinpeygo (budesonide) for the treatment of immunoglobulin A (IgA) nephropathy in adults. Shares are up 9% in Friday afternoon trading. The drug was developed under the name Nefe...

European Commission approves Kinpeygo® for adults with primary IgA nephropathy PR Newswire STOCKHOLM , July 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB ( Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that th...

Shares of Chinook Therapeutics have reacted well recently to a surprising secondary offering conducted at $14.00, providing it with additional capital for the commercialization of atrasentan. Although only one (likely) inferior therapy has been approved for the company’s initia...

NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- As part of its ongoing commitment to raise awareness of both the unique challenges faced by people living with IgA nephropathy and of the resources and support required to help them navigate their journey, Calliditas Therapeutics US, a wholly owne...

Calliditas Therapeutics (NASDAQ:CALT) filed with the SEC for an at-the market-program to sell up to $75M American depositary shares (ADSs) at market price from time to time. The number of ADSs to be sold under the open market sale agreement with Jefferies will depend upon the number...

Calliditas Therapeutics establishes a U.S. At-the-Market Program PR Newswire STOCKHOLM, Sweden , June 28, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas" or "the Company") today an...

FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“ Celularity ”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board o...

A committee of the European Medicines Agency (EMA) recommended the conditional marketing authorization for Calliditas Therapeutics' (NASDAQ:CALT) Kinpeygo to treat symptoms of primary immunoglobulin A nephropathy (IgAN). IgAN is a type of kidney disease which occurs when an antibody...

Calliditas receives positive CHMP opinion in IgA nephropathy PR Newswire STOCKHOLM , May 19, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Committee for Medicinal Products...

Calliditas Therapeutics press release (NASDAQ:CALT): Q1 GAAP EPS of -SEK 3.95. Revenue of SEK 49.7M. Cash amounted to SEK 825.4M and SEK 867.3M as of March 31, 2022 and 2021, respectively. For further details see: Calliditas Therapeutics GAAP EPS of -SEK 3.95, revenue of SEK 49.7M